Although ROCK signaling is a well-established driver of HCC metastasis and chemoresistance, our data reveal a counterintuitive, pathway-specific vulnerability: BRI3BP-high/ROCK-activated cells exhibit heightened sensitivity specifically to the EGFR inhibitor lapatinib. This evidence concerns the gene BRI3BP and hepatocellular carcinoma.